News

Annovis Bio has scheduled a January meeting with the U.S. Food and Drug Administration (FDA) to discuss buntanetap as a treatment for dementia due to Parkinson’s disease. The meeting will include discussions about potential clinical trial design, the criteria that will be used to determine which patients…

Researchers have uncovered a previously overlooked type of electrical brain activity — an irregular signal they call noise — that closely tracks the severity of motor symptoms in people with Parkinson’s disease. The discovery, made by scientists at the Max Planck Institute in Germany, in collaboration with research teams…

A $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will help Booster Therapeutics develop therapeutics to improve the body’s ability to clear disease-causing proteins that drive Parkinson’s disease. The research grant will support studies into small-molecule therapeutics that activate the proteasome, a cellular…

Frequently eating sweets, red meat, and processed meats appears to increase the risk of developing Parkinson’s disease, while consuming more fruits — especially citrus — may be protective against it, according to a large study from Italy. The researchers found, however, that certain nondietary influences were more strongly…

Alector said it is advancing the development of AL050, an enzyme replacement therapy for Parkinson’s disease, with an eye toward submitting an investigational new drug application to the U.S. Food and Drug Administration (FDA) in 2027. “We are well-resourced to advance our portfolio of innovative drug candidates for…

Photopharmics has completed enrollment of a Phase 3 clinical trial testing Celeste, its light therapy device for Parkinson’s disease, the company announced. The ongoing Phase 3 trial (NCT04453033), dubbed Light for PD, has enrolled 350 participants with Parkinson’s, surpassing the initial target enrollment of 300 patients. Topline results…

A $1.9 million U.S. Department of Defense–funded Phase 2 clinical trial will test SwallowFIT, a targeted exercise program designed to retrain the brain’s ability to control the muscles involved in swallowing — a function often compromised in Parkinson’s disease — in active-duty service members, veterans, or their relatives who…

Jotrol, an oral formulation of the natural compound resveratrol, has been cleared for testing in people with Parkinson’s disease by the U.S. Food and Drug Administration (FDA). Jupiter Neurosciences will conduct the Phase 2a clinical trial with Zina Biopharmaceuticals to evaluate the safety, tolerability, and pharmacological properties…

Women with isolated REM sleep behavior disorder (iRBD), an early sign of Parkinson’s disease, exhibit fewer signs of early brain deterioration than men of similar age and disease severity, a study showed. The study, which analyzed the brains of almost 700 people with iRBD and healthy controls, found that women…

Most molecular features in the human brain differ between samples obtained from living individuals and those collected after death, according to new findings from the Living Brain Project, a multiscale investigation from The Friedman Brain Institute in New York. This study, led by researchers at the Icahn School of…